Refine by
Treatment Of Allergic Articles & Analysis
23 news found
What is Newborn Snoring? Oftentimes, newborns breathe noisily when they sleep. It may be caused due to extra mucus or dryness in their tiny nasal passages. However, if you notice your newborn baby actually snoring on a regular basis, consult with a doctor. If your snoring is causing issues with your partner or his/her snoring is irritating you at night, it is important that you seek timely ...
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. “Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant ...
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships. “Dr. Trilla has proven to be an invaluable asset to Intrommune since he ...
GI Innovation licensed out main pipeline, immuno-oncology GI-101 (Simcere China) and allergic disease treatment GI-301 (Yuhan Pharm.) in non-clinical stage value of 2.3 trillion won and currently each pipeline is progressing global clinical 1/2 phase and domestic clinical 1 phase. ...
Louis-Philippe Vézina, CEO of Angany Inc. and Douglas Hein, President of Lincoln Diagnostics Inc. announce the commitment of their respective companies to collaborate on Angany’s outreach to US allergists. A formal agreement to this effect was signed earlier this year. Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome ...
#PeanutAllergyStrong calls on the peanut allergic community, including patients, parents, caregivers and families, to share their peanut allergy stories. ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in targeted populations. The lead program, focused on alleviating allergic diseases, aims to stop asthma before it starts through the disruption of the atopic march. ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of ...
Based on these early efficacy signals, a double blind, randomized, placebo controlled, multicenter, Phase 2b dose selection study was initiated to evaluate the efficacy, safety, and tolerability of B244 topical spray twice daily for 28 days for the treatment of pruritus in 576 adults with a history of mild-to-moderate atopic dermatitis. ...
Based on these early efficacy signals, a double blind, randomized, placebo controlled, multicenter, Phase 2b dose selection study was initiated to evaluate the efficacy, safety, and tolerability of B244 topical spray twice daily for 28 days for the treatment of pruritus in 576 adults with a history of mild-to-moderate atopic dermatitis. ...
“During this global COVID-19 pandemic, many allergy patients are required to stay at home, reducing their ability to visit physicians’ offices for allergy treatments, such as allergy shots,” said Robert Pomrenke, CEO, Allovate. “Upon request, we are making free supplies of our Allerdent® product available for physicians who can provide ...
We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020. With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board ...
Currently, Siolta Therapeutics is focused on the clinical development of a lead product for the prevention and treatment of allergic asthma. "Siolta Therapeutics brings a unique voice to our coalition due to the company's extensive knowledge of the developing infant gut microbiome and its role in targeted human microbiome therapeutics for the prevention and ...
Allovate® retains the global rights to develop products based on the OMIT platform for the treatment of respiratory allergies. Allovate® has licensed the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, which is initially focused on an FDA-approved treatment for peanut allergy. ...
Additionally, many children who suffer from atopic dermatitis in their youth also go on to disproportionally suffer from certain diseases later in life, including 43% of children with severe atopic dermatitis before the age of 8 developing asthma and 45% developing allergic rhinitis according to one recent study.2 “Our goal is to alleviate both the symptoms that are ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia Oxidizing Bacteria (AOB) for ...
“We acknowledge that the regulations set by the German authorities, are important for allergic patients in Germany, the largest European allergy market. Therefore, we were determined to register our sublingual birch and trees products. ...
[BOULDER, COLO] Aktivax, a Boulder County specialty pharmaceutical company, is expanding its team by more than 20 engineers and other technical staff after being awarded a Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Agency (BARDA) contract to continue developing its auto-injector platform ARAI. Under an 18-month, $15 million contract with BARDA, ...
ROXALL Medizin in Hamburg and the Portuguese Pharma group BIAL have signed a contract. ROXALL takes over the allergy-section that, till now, was known as BIAL-Aristeguí. With this acquisition ROXALL provides the base for further growth. The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of ...